Carbocisteine: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the local prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Excessive mucus or sputum

Adult: Initially, 2,250 mg daily in divided doses, reduce to 1,500 mg daily when satisfactory response is obtained.
Child: 2-5 years 62.5-125 mg 4 times daily; 6-12 years 250 mg tid.

Administration

Should be taken with food.

Contraindications

Active peptic ulceration. Children <2 years.

Special Precautions

Patient with history of gastroduodenal ulcers, bronchospasm, asthma or respiratory failure. Debilitated patients. Children ≥2 years. Pregnancy and lactation.

Adverse Reactions

Significant: Gastrointestinal bleeding. Rarely, urticaria and bronchospasm.
Immune system disorders: Anaphylactic reactions, fixed drug eruption.
Gastrointestinal disorders: Nausea, vomiting, diarrhoea, gastric discomfort.
Respiratory, thoracic and mediastinal disorders: Bronchorrhea.
Skin and subcutaneous tissue disorders: Rashes. Rarely, bullous dermatitis (e.g. Stevens-Johnson syndrome, erythema multiforme).

Overdosage

Symptoms: Gastrointestinal disturbance (e.g. gastralgias, nausea, vomiting). Management: May perform gastric lavage, followed by observation.

Action

Description: Carbocisteine reduces goblet cell hyperplasia and therefore plays a role in the management of disorders characterised by abnormal mucous.
Pharmacokinetics:
Absorption: Rapidly and well absorbed from the gastrointestinal tract. Time to peak plasma concentration: Approx 2 hours (range: 1-3 hours).
Distribution: Penetrates into lung tissue and respiratory mucous.
Metabolism: Metabolised in the liver via acetylation, decarboxylation and sulfoxidation.
Excretion: Via urine (as unchanged drug and metabolites). Elimination half-life: 1.87 hours (range: 1.4-2.5 hours).

Chemical Structure

Storage

Syrup: Store below 25°C. Tab/cap: Store below 30°C.

MIMS Class

Cough & Cold Preparations

ATC Classification

R05CB03 - carbocisteine ; Belongs to the class of mucolytics. Used in the treatment of wet cough.

References

Anon. Carbocisteine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 06/05/2020.

Buckingham R (ed). Carbocisteine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/05/2020.

Carbocisteine 375 mg Capsule, Hard (Key Pharmaceuticals Ltd). MHRA. https://products.mhra.gov.uk/. Accessed 06/05/2020.

Joint Formulary Committee. Carbocisteine. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 06/05/2020.

Pabron Cough Kids Syrup (Xepa-Soul Pattinson Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my/. Accessed 18/06/2020.

Pabron Cough Tablet (Xepa-Soul Pattinson Sdn Bhd). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my/. Accessed 18/06/2020.

Rhinathiol Syrup (Sanofi). MIMS Singapore. http://www.mims.com/singapore. Accessed 18/06/2020.

Disclaimer: This information is independently developed by MIMS based on Carbocisteine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by MIMS.com